post neoadjuvant therapy: issues in interpretation · reporting post neoadjuvant chemotherapy...
TRANSCRIPT
![Page 1: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/1.jpg)
Post Neoadjuvant therapy: issues in
interpretation
![Page 2: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/2.jpg)
Disclosure:
![Page 3: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/3.jpg)
Overview D
Prognostic features in assessment of post treatment specimens:
Tumor size
Cellularity
Grade
Receptors
LN
![Page 4: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/4.jpg)
Neoadjuvant chemotherapy: receiving chemotherapy before surgery
Adjuvant: Chemotherapy after surgery
![Page 5: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/5.jpg)
Who are the candidates
Offered to LABC patients to reduce the size
Improves the surgical options
NACT achieve the same survival results as adjuvant
![Page 6: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/6.jpg)
Advantages of NACT
In vivo assessment of tumor response to different systemic interventions
Pathologically detected residual disease predicts prognosis
Increased eligibility for breast conservation
![Page 7: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/7.jpg)
Tumor bed visible
the periphery residual tumor nodules may or may not be visible
Measure: TB, residual nodules and distance to margins
post-ttt
How to approach a specimen post NACT
![Page 8: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/8.jpg)
Tumor bed is not visible:
Radiology report (residual calcs, response, location)
Clip inserted at the time of the biopsy
Send specimen to imaging
post-ttt
![Page 9: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/9.jpg)
If the specimen is small, tumor bed not clearly
image the specimen, could submit sections guided by location of clip
If the tumor bed is large > 5 cm (variability in guidelines)
Start with 1-2 blocks/1cm, if no residual tumour is found submit in toto
How many sections are enough?
![Page 10: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/10.jpg)
What is pCR 1.No residual invasive tumor in the breast and lymph node
2.No residual invasive or in situ carcinoma in the breast and lymph node
3.No residual invasive carcinoma in the breast
4.No residual invasive carcinoma in the lymph node
![Page 11: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/11.jpg)
pCR
Powerful predictor of long-term outcome(OS and DFS)pCR
pCR: as absence of residual invasive disease in the breast and ipsilateral lymph nodes after NACT
(ypT0/isypN0)
![Page 12: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/12.jpg)
pCR related to several factors
Higher tumor grade
Proliferative fraction
Hormone receptor status (TN and HER2 +ve)
![Page 13: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/13.jpg)
Sorlie et al, Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23.
ve usually achieve pCR while luminal A tumours are least likely,
Luminal B intermediate respond) (Rouzier et al 2005)
![Page 14: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/14.jpg)
Triple Negative
Core bx ER PR
HER2 Tumor bed LN
![Page 15: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/15.jpg)
HER2 positive
Core bx � ER� PR�
HER2� Tumor bed � LN �
![Page 16: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/16.jpg)
Luminal B HER2 positive
Core bx ER PR
HER2 Post ttt LN
![Page 17: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/17.jpg)
Luminal B
Core bx ER PR
HER2 Post ttt LN
![Page 18: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/18.jpg)
Reporting post Neoadjuvant Chemotherapy
Residual invasive carcinoma (size - cellularity)
Tumor bed
Grade
Margins
Receptors
LN
![Page 19: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/19.jpg)
How can we identify the tumor bed ?
pCR or near pCR
If carcinoma is not palpable
![Page 20: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/20.jpg)
Tumor bed Loosely vascularized fibrotic area
with absence of normal glands
Fibromyxoid stroma
Mucin pools (if no epithelial cells present should not be considered residual tumour)
hemosiderin deposition and absence of normal mammary glandular elements
![Page 21: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/21.jpg)
Residual tumor Residual tumor: most
show decrease in cellularity.
Single cells, cords or
stroma, multiple residual foci or a mass that has shrunk in size circumferentially
Cytologic features: Hyper eosinophilic cytoplasm, nuclear enlargement and vesicular chromatin
Pre-ttt Post-ttt
Post-ttt Post-ttt
Post-ttt Post-ttt
![Page 22: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/22.jpg)
Tumor size
If response is minimal, tumour is
If response is marked, multiple small foci dispersed over a large tumour bed
The size of the largest continuous focus and the number of residual foci should be reported
![Page 23: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/23.jpg)
Tumor cellularity Carcinomas are often less
cellular post NACT
Loss of cellularity is not always
which can lead to clinical overestimation
Cellularity is determined with accuracy only if pretreatment specimen is available for comparison
Loss of cellularity is associated with better prognosis and clinical outcome
(Ogston et al, 2003)
![Page 24: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/24.jpg)
Chen A at MD Anderson found that a residual tumor > 2.0 cm is associated with higher LRR
Multifocal disease is associated with higher LRR
5 year LRR-free survival for multifocal residual, solitary residual and no residual was 82%, 93% and 95%.
(Chen A M et al , 2004)
![Page 25: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/25.jpg)
Reporting post Neoadjuvant Chemotherapy
Residual invasive carcinoma (size - cellularity)
Tumor bed
Grade
Margins
Receptors
LN
![Page 26: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/26.jpg)
Histologic grade correlation with Outcomes
Elston & Ellis (1991) Histopathology 19:403
Score Tubule formation Nuclear pleomorphism
Mitotic counts *
1 >75 % similar to normal 0-9
2 10-75% Larger than normal, nucleoli
10-19
3 <10% Marked, large and bizarre
>20
* Mitotic counts depend on field diameter
![Page 27: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/27.jpg)
Nottingham grade Usually the same
NACT causes increased pleomorphism of residual cells
Mitotic activity is reduced in addition to reduction in tumor cellularity which can
mitotic count Pre-ttt Post-ttt
![Page 28: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/28.jpg)
The pretreatment assessment of histological grade remains an independent prognostic factor for DFS and OS
Post NACT grade important ? retains its prognostic value with lower tumour grades associated with better survival
(Pierga et al 2003)
![Page 29: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/29.jpg)
Hormone receptors and HER2
![Page 30: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/30.jpg)
In untreated tumors, minimal discordance between core needle and excisional biopsy has been reported
ER (discordance 1.8%)
PR (discordance 15%)
HER2 (discordance 1.2%)
(Ardenos M et al, 2009)
![Page 31: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/31.jpg)
Hormone receptors can change after treatment
A change in HR status has been reported in 8 - 33% of patients.
For ER, half the discordance was from negative to positive
For PgR, changes from a positive to a negative result was commonly seen
(Van de Ven S etal, 2011)
![Page 32: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/32.jpg)
Tumor heterogeneity
Limited amount present either before or after treatment
Selection: if multiple tumors or heterogenous expression some foci respond to therapy more than others
Technical factors has to be considered as well
![Page 33: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/33.jpg)
HER2
Changes in HER2 after untargeted therapy are uncommon
Some studies reported decrease in expression of HER2 on IHC but in situ hibridization is not changed due to stable HER2 gene
![Page 34: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/34.jpg)
Reporting after Neoadjuvant chemotherapy
Residual invasive carcinoma (size - cellularity)
Tumor bed
Grade
Margins
Receptors
LN
![Page 35: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/35.jpg)
Lymph nodes
Number of involved lymph nodes
Size of the deposits
EXtranodal extension
Lymph nodes showing treatment effects
![Page 36: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/36.jpg)
Lymphoid depletion
Fibrous scarring with little or no residual tumour
LN metasases with CR are often
aggregates of macrophages
Should not be considered
LN
![Page 37: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/37.jpg)
LMWK �
![Page 38: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/38.jpg)
Micrometastases/ITC
Post NACT micrometastases/ITC are mostly considered macro metastases that partially responded to therapy
(Newman LA et al, 2003)
![Page 39: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/39.jpg)
Post NACT lymph node status is the most important prognostic factor.
LN response after chemotherapy is a better prognostic factor than response of the primary tumor to primary chemotherapy
(Rouzier R et al JCO, 2002).
![Page 40: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/40.jpg)
Fig 2.
Rouzier R et al. JCO 2002;20:1304-1310
©2002 by American Society of Clinical Oncology
Distant disease-free survival according to the axillary nodal status after primary chemotherapy. —, No residual nodal disease; ---, residual nodal disease.�
![Page 41: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/41.jpg)
Number of involved nodes: The increased number of LN with residual positive lymph nodes is associated with worse DFS
Size of the deposit: The larger the size of the metastatic deposit the worse the DFS
![Page 42: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/42.jpg)
Systems for evaluating response to treatment
American Joint Committee on Cancer system: adds the
Relies mainly on tumor size post treatment and lymph node status in the post treatment specimen
Tumor size : based on the size of largest continuos
added.
The categories are the same as those used for the pre-ttt
Disadvantage: cellularity is not included in the overall assessment
![Page 43: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/43.jpg)
The Miller-Payne System: divided into 5 grades based on pre and post treatment cellularity and was correlated with OS and DFS
Disadvantage: Doesn’t include response in the lymph node
(Ogston K et al, 2003)
![Page 44: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/44.jpg)
Residual cancer burden:
Residual invasive carcinoma cellularity
Number of lymph nodes with metastases
Size of the largest metastatic deposit
Combined to provide a continuos parameter of response (RCB index) divided into four categories
![Page 45: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/45.jpg)
Reporting after neo-adjuvant chemotherapy
Tumor bed
Size of the largest continuous focus or number of foci over the tumor bed
Grade
Margins
LN (number and size of met)
![Page 46: Post Neoadjuvant therapy: issues in interpretation · Reporting post Neoadjuvant Chemotherapy Residual invasive carcinoma (size - cellularity) Tumor bed Grade Margins Receptors](https://reader034.vdocuments.site/reader034/viewer/2022050511/5f9b905ad10f535dc076893b/html5/thumbnails/46.jpg)